The mechanism of the most abundant protein that composes the Ebola virus, VP 40, mediating replication of a new viral particle has been investigated by a team of scientists. The team consists of Robert Stahelin, an adjunct associate professor of chemistry and biochemistry at the University of Notre Dame and an associate professor at the Indiana University School of Medicine-South Bend, as well as a member of Notre Dame's Eck Institute for Global Health.
"In brief, the Ebola virus has just seven proteins that encode in its genome," Stahelin said. "VP40 is critical to the formation of a new viral particle and it does this by interacting with lipids inside human cells." Stahelin and co-investigator Smita Soni, a postdoctoral researcher at the Indiana University School of Medicine, found that VP40 is able to assemble in vitro (i.e., in a test tube), without any human cells present and mediate formation of virus-like particles when the human lipid phosphatidylserine is found in solution with VP40, but not other control lipids.
Quiz on Ebola
Why is the deadly Ebola virus outbreak making the health experts hit the panic button? Find out from this quiz.
"This means, in conjunction with our previous research papers, that Ebola virus VP40 can assemble and interact with human phosphatidylserine to generate the lipid coat of the virus," Stahelin said. "For completeness sake, Ebola virus is a lipid-enveloped virus and gets its lipid bilayer coat from the human cell it infects. In essence, Ebola VP40 is assembling on phosphatidylserine-enriched regions of human cells to form the long filamentous virus particle we are so familiar with seeing."
Experimental Ebola Vaccine Shows Mild Side Effects: Geneva Hospital
An experimental vaccine against the deadly Ebola virus has provoked only mild side effects in volunteers in Switzerland, claims Geneva hospital.
"It seems that the Ebola crisis is being managed better than months earlier and in some regions, especially those in Liberia, hasn't been spreading at the rates seen earlier," he said. "However, it will still be nine months, if not more, before full control can be obtained. The recent spread to Mali is of concern. "Stahelin's and Soni's study appears in the Journal of Biological Chemistry.
Source: Eurekalert
Ebola Virus Disease
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have identified five types of Ebola or Ebola hemorrhagic fever virus.
First Human Trials of Ebola Vaccine is Promising: NIH
A Phase 1 trial of Ebola vaccine is showing promising results, say researchers, adding that they are one step closer to developing Ebola vaccine.
Recommended Reading
Latest Research News
